The NIMML has established an extensible innovation pipeline for developing safer and more effective therapeutics for immune-mediated, infectious and chronic inflammatory diseases.
Pioneering NIMML program aimed at understanding how diet and nutritional factors influence the immune responses, thereby regulating health and disease outcomes.
The NIMML aims to comprehensively and systematically characterize mechanisms of immune dysregulation that contribute to the pathogenesis of inflammatory bowel disease (IBD), Type-1 Diabetes, psoriasis, asthma, allergies, and rheumatoid arthritis.
The NIMML combines experimental and computational methods to study the mechanisms of action underlying immune responses to H. pylori, E. coli, C. difficile, and influenza virus.
The NIMML is identifying and validating novel therapeutic targets for the treatment of type-2 diabetes and developing lead compounds that can modulate these novel targets.
Computational immunology, or immunoinformatics, has emerged as a powerful tool to quantitatively understand the dynamics of complex immunological systems.
|Tariq Ayubi||BREU Student|
|Michael Bagnoli||BREU Student|
|Zachary Baker||BREU Student|
|David Bevan||Visiting Scholar|
|Stanca Ciupe||Visiting Scholar|
|Xinwei Deng||Visiting Collaborator|
|Shivani Garg||BREU Student|
|Kathryn Hayes||BREU Student|
|Varun Kumar||BREU Student|
|Wyatt Lansford||BREU Student|
|Samuel Light||USP Student|
|Erin Lim||BREU Student|
|William Newcomer||BREU Student|
|Colin Ocampo||BREU Student|
|Collin Ocampo||BREU Student|
|Sara Prince||BREU Student|
|Andrew Shedlock||BREU Student|
|Nuria Tubau Juni||Graduate Research Assistant|
|Meghna Verma||Graduate Research Assistant|
|Carly Westermann||BREU Student|